Compositions and methods for treating retinal degradation
US11717520B2 · kind B2 · utility
1Cited by
12References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 2, 2021 |
| Grant date | Aug 8, 2023 |
| Priority date | — |
| Expiry date | May 21, 2041 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to compounds and compositions that inhibit the NLRP3 inflammasome, for example, or a pharmaceutically acceptable salt thereof. Also disclosed are methods for treating, and in particular methods for treating macular degeneration, e.g., dry age-related macular degeneration (AMD) and wet AMD, Alzheimer's disease, multiple sclerosis, and Parkinson's disease, using compounds and compositions that inhibit the NLRP3 inflammasome.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.